These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 22329580)
1. Immunotherapy for malignant melanoma. Zeiser R; Schnitzler M; Andrlova H; Hellige T; Meiss F Curr Stem Cell Res Ther; 2012 May; 7(3):217-28. PubMed ID: 22329580 [TBL] [Abstract][Full Text] [Related]
2. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma]. Lotem M; Merims S; Frank S; Ospovat I; Peretz T Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667 [TBL] [Abstract][Full Text] [Related]
3. Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma. Lens M; Testori A; Ferucci PF Curr Top Med Chem; 2012; 12(1):61-6. PubMed ID: 22196270 [TBL] [Abstract][Full Text] [Related]
5. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316 [TBL] [Abstract][Full Text] [Related]
6. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies. Ascierto PA Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic use of anti-CTLA-4 antibodies. Blank CU; Enk A Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Di Giacomo AM; Danielli R; Guidoboni M; CalabrĂ² L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884 [TBL] [Abstract][Full Text] [Related]
9. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Graziani G; Tentori L; Navarra P Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211 [TBL] [Abstract][Full Text] [Related]
13. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069 [TBL] [Abstract][Full Text] [Related]